Nat Med

ADA 2024: Semaglutide cuts kidney-disease, CV events in T2DM patients

June 26, 2024

Findings from the FLOW trial, the first dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist, were presented at the recent American Diabetes Association annual meeting. Investigators found that semaglutide use significantly reduced the risk of major kidney disease events and cardiovascular outcomes in patients with T2D and chronic kidney disease.

• FLOW trial participants with T2D and chronic kidney disease (CKD) were stratified by baseline SGLT2i use (N = 550) or no use (N = 2,983) and randomized to semaglutide/placebo. The primary outcome was a composite of kidney failure, ≥50% eGFR reduction, kidney or cardiovascular death.
• The risk of the primary outcome was 24% lower in all participants treated with semaglutide vs placebo (95% confidence interval [CI] 34%, 12%). The primary outcome occurred in 41/277 (semaglutide) versus 38/273 (placebo) participants on SGLT2i at baseline, and in 290/1,490 versus 372/1,493 participants not taking SGLT2i at baseline.
• Treatment differences favoring semaglutide for total eGFR slope were 0.75 in the SGLT2i subgroup and 1.25 in non-SGLT2i-subgroup, P-interaction 0.237.
• Semaglutide benefits on major cardiovascular events and all-cause death were similar regardless of SGLT2i use (P-interaction 0.741 and 0.901, respectively). The benefits of semaglutide in reducing kidney outcomes were consistent in participants with/without baseline SGLT2i use; power was limited to detect smaller but clinically relevant effects

Sources:

Mann JFE, et al. (2024, June 24). Nat Med. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. https://pubmed.ncbi.nlm.nih.gov/38914124/

(2024, June 24). American Diabetes Association. Semaglutide reduced risk for major kidney disease events by 24% for patients with type 2 diabetes and kidney disease. https://diabetes.org/newsroom/press-releases/semaglutide-reduced-risk-major-kidney-disease-events-24-patients-type-2